Clareo Health | A Study to Assess Real-World Use and Outcomes of TAR-200 for Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) in the United States
Has a confirmed diagnosis of NMIBC based on TURBT or cold cup biopsy
Initiated first dose of TAR-200 in a real-world setting within 6 weeks prior to baseline visit/Study visit 1
Participants with childbearing potential are required to adhere to contraceptive recommendations as specified in the approved product labeling for TAR-200. Additionally, participants should seek consultation with their physician for personalized contraceptive advice
Must provide informed consent as described in the protocol
You may not be if
Has any medical condition deemed by the health care practitioner (HCP) as contraindicated to receive TAR-200 treatment
Had previous treatment with TAR-200 discontinued prior to baseline visit/Study visit 1
Previously received TAR-200 intravesically as part of a clinical trial(s)
Previously received greater than (\>) 2 doses/cycles of TAR-200 in the real-world setting
Currently participating in an interventional bladder cancer clinical trial
